Document is current
Any future updates will be listed below
-
Authors
Mao, Ninghui
Zhang, Zeda
Lee, Young Sun
Choi, Danielle
Rivera, Aura Agudelo
Li, Dan https://orcid.org/0000-0002-8777-4580
Lee, Cindy
Haywood, Samuel
Chen, Xiaoping
Chang, Qing
Xu, Guotai
Chen, Hsuan-An https://orcid.org/0000-0002-8979-3670
de Stanchina, Elisa
Sawyers, Charles https://orcid.org/0000-0003-4955-6475
Rosen, Neal https://orcid.org/0000-0002-8307-654X
Hsieh, Andrew C. https://orcid.org/0000-0002-0897-1050
Chen, Yu https://orcid.org/0000-0002-0171-3884
Carver, Brett S. https://orcid.org/0000-0001-5165-3544
-
Funding
Funding for this research was provided by:
Starr Foundation
- License Information
-
More Information
Article History
Received: 23 December 2020
Accepted: 5 August 2021
First Online: 20 August 2021
Competing interests
: C.L.S. is co-inventors of enzalutamide and apalutamide and may be entitled to royalties. C.L.S. serves on the Board of Directors of Novartis and is a co-founder of ORIC Pharm. He is a science advisor to Agios, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, Petra, and PMV. He was a co-founder of Seragon, purchased by Genentech/Roche in 2014. N.R. is on the scientific advisory board (SAB) and receives research funding from Chugai, on the SAB and owns equity in Beigene, and Fortress. N.R. is also on the SAB of Daiichi-Sankyo, Astra-Zeneca-MedImmune, and F-Prime, and is a past SAB member of Millenium-Takeda, Kadmon, Kura, and Araxes. N.R. is a consultant to Novartis, Boehringer Ingelheim, Tarveda, and Foresight and consulted in the last three years with Eli Lilly, Merrimack, Kura Oncology, Araxes, and Kadman. N.R. owns equity in ZaiLab, Kura Oncology, Araxes, and Kadman. N.R. collaborates with Plexxikon. A.C.H. has received research funding from eFFECTOR Therapeutics. The remaining authors declare no competing interests.
